Machine Program

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 86292 Experts worldwide ranked by ideXlab platform

Alessandro G Digesu - One of the best experts on this subject based on the ideXlab platform.

  • transcutaneous posterior tibial nerve stimulation versus extended release oxybutynin in overactive bladder patients a prospective randomized trial
    European Journal of Obstetrics & Gynecology and Reproductive Biology, 2016
    Co-Authors: Valentin Manriquez, Rodrigo Guzman, Michel Naser, Amalia Aguilera, Simonie Narvaez, Ariel Castro, Steven Swift, Alessandro G Digesu
    Abstract:

    Abstract Introduction and hypothesis The aim of this study was to evaluate the effectiveness of transcutaneous posterior tibial nerve stimulation (T.C. PTNS) versus extended release oxybutynin (E.R.O.) in patients with overactive bladder. Materials and methods Seventy female patients were randomized to receive either 10 mg E.R.O. daily or T.C. PTNS, using a TENS Machine Program with the 20 Hz, 200 cycles/s, and normal stimulation setting for two 30-min sessions, each week for a 12-week period. Pre-treatment and after the 12-week intervention, each patient completed a 3-day voiding diary and a self-report quality of life questionnaire (OAB-q). Statistical analysis was performed using Stata V12.1. Results Sixty-four patients completed the treatment protocol. There were no significant differences between study groups in terms of age, body mass index, past hormone replacement therapy, smoking habits, menopause status, and parity. Prior to treatment, there were also no significant differences in the analysis of the 3-day voiding diary or in the OAB-q questionnaire results. Following the 12-week study, there was a statistically significant reduction in frequency of urination, urgency episodes, and urge incontinent episodes compared to pre-treatment values. However, there were no significant differences in these values between intervention groups after 12-weeks of therapy. There was a similar improvement in OAB-q scores in both treatment groups following therapy, and the T.C. PTNS group showed a statistically significant improvement over the E.R.O. in domain 2 of the OAB-q questionnaire. The other two domains showed similar improvement in both study groups. Conclusion T.C. PTNS and E.R.O. demonstrated similar improvements in subjects with OAB in a 12-week study.

Digesu G. Alessandro - One of the best experts on this subject based on the ideXlab platform.

  • Transcutaneous posterior tibial nerve stimulation versus extended release oxybutynin in overactive bladder patients. A prospective randomized trial
    'Elsevier BV', 2016
    Co-Authors: Manríquez Galán Valentín, Guzmán Rojas Rodrigo, Naser Nassar Michel, Aguilera Amalia, Narvaez Simonie, Castro Lara Ariel, Swift Steven, Digesu G. Alessandro
    Abstract:

    Artículo de publicación ISIIntroduction and hypothesis: The aim of this study was to evaluate the effectiveness of transcutaneous posterior tibial nerve stimulation (T.C. PTNS) versus extended release oxybutynin (E.R.O.) in patients with overactive bladder. Materials and methods: Seventy female patients were randomized to receive either 10 mg E.R.O. daily or T.C. PTNS, using a TENS Machine Program with the 20 Hz, 200 cycle/s, and normal stimulation setting for two 30-min sessions, each week for a 12-week period. Pre-treatment and after the 12-week intervention, each patient completed a 3-day voiding diary and a self-report quality of life questionnaire (OAB-q). Statistical analysis was performed using Stata V12.1. Results: Sixty-four patients completed the treatment protocol. There were no significant differences between study groups in terms of age, body mass index, past hormone replacement therapy, smoking habits, menopause status, and parity. Prior to treatment, there were also no significant differences in the analysis of the 3-day voiding diary or in the OAB-q questionnaire results. Following the 12-week study, there was a statistically significant reduction in frequency of urination, urgency episodes, and urge incontinent episodes compared to pre-treatment values. However, there were no significant differences in these values between intervention groups after 12-weeks of therapy. There was a similar improvement in OAB-q scores in both treatment groups following therapy, and the T.C. PTNS group showed a statistically significant improvement over the E.R.O. in domain 2 of the OAB-q questionnaire. The other two domains showed similar improvement in both study groups. Conclusion: T.C. PTNS and E.R.O. demonstrated similar improvements in subjects with OAB in a 12-week study

Maurice Margenstern - One of the best experts on this subject based on the ideXlab platform.

  • non erasing turing Machines a new frontier between a decidable halting problem and universality
    Latin American Symposium on Theoretical Informatics, 1995
    Co-Authors: Maurice Margenstern
    Abstract:

    We define a new criterion which allows to separate cases when all non erasing Turing Machines on {0, 1} have a decidable halting problem from cases where a universal non erasing Machine can be constructed. It is the case of the number of left instructions in the Machine Program. In this paper we give the main ideas of the proof for both parts of the frontier result. We prove that there is a universal non-erasing Turing Machine whose Program has precisely 3 left instructions and that the halting problem is decidable for any non-erasing Turing Machine on alphabet {0, 1}, the Program of which contains at most 2 left instructions. For this latter result, we have a uniform decision algorithm.

  • non erasing turing Machines a frontier between a decidable halting problem and universality
    Fundamentals of Computation Theory, 1993
    Co-Authors: Maurice Margenstern
    Abstract:

    A new criterion, namely the number of colours used by the instructions of a Turing Machine Program, is proposed to settle the frontier between a decidable halting problem and universality for Turing Machines. The efficiency of this criterion has been proved by Pavlotskaia, [3, 4], for deterministic Turing Machines on alphabet {0,1}. It is used here in the case of non-erasing Turing Machines on the same alphabet.

Valentin Manriquez - One of the best experts on this subject based on the ideXlab platform.

  • transcutaneous posterior tibial nerve stimulation versus extended release oxybutynin in overactive bladder patients a prospective randomized trial
    European Journal of Obstetrics & Gynecology and Reproductive Biology, 2016
    Co-Authors: Valentin Manriquez, Rodrigo Guzman, Michel Naser, Amalia Aguilera, Simonie Narvaez, Ariel Castro, Steven Swift, Alessandro G Digesu
    Abstract:

    Abstract Introduction and hypothesis The aim of this study was to evaluate the effectiveness of transcutaneous posterior tibial nerve stimulation (T.C. PTNS) versus extended release oxybutynin (E.R.O.) in patients with overactive bladder. Materials and methods Seventy female patients were randomized to receive either 10 mg E.R.O. daily or T.C. PTNS, using a TENS Machine Program with the 20 Hz, 200 cycles/s, and normal stimulation setting for two 30-min sessions, each week for a 12-week period. Pre-treatment and after the 12-week intervention, each patient completed a 3-day voiding diary and a self-report quality of life questionnaire (OAB-q). Statistical analysis was performed using Stata V12.1. Results Sixty-four patients completed the treatment protocol. There were no significant differences between study groups in terms of age, body mass index, past hormone replacement therapy, smoking habits, menopause status, and parity. Prior to treatment, there were also no significant differences in the analysis of the 3-day voiding diary or in the OAB-q questionnaire results. Following the 12-week study, there was a statistically significant reduction in frequency of urination, urgency episodes, and urge incontinent episodes compared to pre-treatment values. However, there were no significant differences in these values between intervention groups after 12-weeks of therapy. There was a similar improvement in OAB-q scores in both treatment groups following therapy, and the T.C. PTNS group showed a statistically significant improvement over the E.R.O. in domain 2 of the OAB-q questionnaire. The other two domains showed similar improvement in both study groups. Conclusion T.C. PTNS and E.R.O. demonstrated similar improvements in subjects with OAB in a 12-week study.

Manríquez Galán Valentín - One of the best experts on this subject based on the ideXlab platform.

  • Transcutaneous posterior tibial nerve stimulation versus extended release oxybutynin in overactive bladder patients. A prospective randomized trial
    'Elsevier BV', 2016
    Co-Authors: Manríquez Galán Valentín, Guzmán Rojas Rodrigo, Naser Nassar Michel, Aguilera Amalia, Narvaez Simonie, Castro Lara Ariel, Swift Steven, Digesu G. Alessandro
    Abstract:

    Artículo de publicación ISIIntroduction and hypothesis: The aim of this study was to evaluate the effectiveness of transcutaneous posterior tibial nerve stimulation (T.C. PTNS) versus extended release oxybutynin (E.R.O.) in patients with overactive bladder. Materials and methods: Seventy female patients were randomized to receive either 10 mg E.R.O. daily or T.C. PTNS, using a TENS Machine Program with the 20 Hz, 200 cycle/s, and normal stimulation setting for two 30-min sessions, each week for a 12-week period. Pre-treatment and after the 12-week intervention, each patient completed a 3-day voiding diary and a self-report quality of life questionnaire (OAB-q). Statistical analysis was performed using Stata V12.1. Results: Sixty-four patients completed the treatment protocol. There were no significant differences between study groups in terms of age, body mass index, past hormone replacement therapy, smoking habits, menopause status, and parity. Prior to treatment, there were also no significant differences in the analysis of the 3-day voiding diary or in the OAB-q questionnaire results. Following the 12-week study, there was a statistically significant reduction in frequency of urination, urgency episodes, and urge incontinent episodes compared to pre-treatment values. However, there were no significant differences in these values between intervention groups after 12-weeks of therapy. There was a similar improvement in OAB-q scores in both treatment groups following therapy, and the T.C. PTNS group showed a statistically significant improvement over the E.R.O. in domain 2 of the OAB-q questionnaire. The other two domains showed similar improvement in both study groups. Conclusion: T.C. PTNS and E.R.O. demonstrated similar improvements in subjects with OAB in a 12-week study